摘要脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA2)是磷脂酶A2超家族的一个亚型,主要由巨噬细胞和淋巴细胞产生.Lp-PLA2选择性水解低密度脂蛋白颗粒表面的氧化型磷脂,产生溶血磷脂胆碱和氧化型游离脂肪酸.Lp-PLA2表达于动脉粥样硬化斑块和不稳定斑块纤维帽内的巨噬细胞.研究表明,缺血性卒中患者血浆Lp-PLA2活性显著增高,而Lg-PLA2可能成为预测缺血性脑血管事件的独立危险因素.选择性LP-PLA2抑制剂可减轻炎症反应,增强斑块稳定性,抑制动脉粥样硬化斑块形成,有可能成为抗动脉粥样硬化斑块形成的一类新型药物.

abstractsThe lipoprotein-associated phospholipase A2 (Lp-PLA2), a subtype of the phospholipase A2 superfamily, is produced primarily by macrophages and lymphocytes. Lp-PLA2specifically hydrolyzes oxidized phospholipids on oxidized low-density lipoprotein particles,resulting in production of lysophosphatidylcholine and oxidized fatty acids. Lp-PLA2 is expressed in atherosclerotic plaques and in macrophages within a fibrous cap of unstable plaque.Studies haw shown that the plasma Lp-PLA2 activity increases significantly in patients with ischemic stroke, and Lp-PLA2 may become an independent risk factor for predicting ischemic cerebrovascular events. The selective Lp-PLA2 inhibitor can reduce the inflammatory response,enhance the stability of plaques, and inhibit the formation of atherosclerotic plaques, and may become a new class of drugs for preventing the formation of atherosclerotic plaques.